View More Recent Stories
-
Vertex Pharma (VRTX): Health Canada Grants Marketing Authorization for TRIKAFTA for People With Cystic Fibrosis Aged 2 Years and Older With Certain Rare Mutations
-
Vertex Pharma (VRTX) Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for CF
-
Redburn-Atlantic Starts Vertex (VRTX) at Buy
-
Vertex Pharma (VRTX) to Present Positive Results From Ongoing Phase 1/2 Study of VX-880
-
Vertex (VRTX) PT Raised to $550 at Argus
-
Vertex (VRTX) PT Lowered to $421 at RBC Capital
-
Vertex Researchers Awarded 2024 Breakthrough Prize in Life Sciences
